| Lu, Hongzhou |
| Completed | 3 | 1369 | RoW | JT001, VV116, Placebo | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Mild to Moderate COVID-19 | 02/23 | 02/23 | | |
NCT05716425: Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) |
|
|
| Completed | 3 | 1218 | RoW | STI-1558, STI-1558 placebo | Zhejiang ACEA Pharmaceutical Co. Ltd. | COVID-19 | 07/23 | 07/23 | | |
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19 |
|
|
| Completed | 2/3 | 150 | RoW | Meplazumab for Injection, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Covid19 | 09/22 | 10/22 | | |
NCT05675072: Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 |
|
|
| Recruiting | 2/3 | 1336 | RoW | FB2001, FB2001 for Inhalation, FB2001 placebo, placebo | Frontier Biotechnologies Inc. | Mild to Moderate COVID-19 | 09/23 | 12/23 | | |
NCT05702788: Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) |
|
|
| Withdrawn | 2 | 168 | NA | Jaktinib hydrochloride tablets, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | COVID-19, Pneumonia | 04/24 | 04/24 | | |
NCT06288893: Phase II Clinical Study of SHEN211 Tablets in the Treatment of Mild and Moderate Novel Corona Virus Infection (COVID-19) |
|
|
| Not yet recruiting | 2 | 30 | RoW | SHEN211 Tablets, Test group, Placebo for SHEN211 Tablets, control group | JKT Biopharma Co., Ltd. | COVID-19 | 08/24 | 01/25 | | |
NCT05369676: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 |
|
|
| Completed | 1/2 | 32 | RoW | SSD8432 dose 1/Ritonavir, SIM0417 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir, SIM0417 dose 2/Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 Patients | 08/22 | 08/22 | | |
NCT05523739: Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients |
|
|
| Completed | 1 | 79 | RoW | STI-1558 | Zhejiang ACEA Pharmaceutical Co. Ltd. | SARS-CoV-2 Infection | 12/22 | 03/23 | | |
| Active, not recruiting | 1 | 45 | RoW | ICVAX, Placebo | Immuno Cure Holding (HK) Limited, Shenzhen Third People's Hospital, Shenzhen Immuno Cure Biomedical Company Limited | Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection | 09/24 | 01/25 | | |
NCT05038449: Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 |
|
|
| Not yet recruiting | N/A | 60 | RoW | Colchicine Tablets, Standard therapy | Shanghai Public Health Clinical Center, Kunming Pharmaceuticals, Inc. | Covid19, Colchicine | 06/23 | 09/23 | | |
